Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by LSV Asset Management

LSV Asset Management lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 75.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 131,800 shares of the specialty pharmaceutical company's stock after acquiring an additional 56,500 shares during the period. LSV Asset Management owned approximately 0.40% of Collegium Pharmaceutical worth $4,057,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacer Advisors Inc. boosted its stake in shares of Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company's stock valued at $66,938,000 after purchasing an additional 883,380 shares in the last quarter. SummerHaven Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company's stock worth $1,048,000 after buying an additional 368 shares in the last quarter. Natixis Advisors L.P. lifted its position in Collegium Pharmaceutical by 152.9% in the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company's stock valued at $1,215,000 after acquiring an additional 32,865 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Collegium Pharmaceutical by 32.7% during the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company's stock valued at $6,116,000 after purchasing an additional 67,439 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in Collegium Pharmaceutical by 1,475.5% in the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company's stock worth $6,190,000 after buying an additional 188,347 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL traded down $0.20 on Thursday, hitting $37.86. 363,953 shares of the company's stock traded hands, compared to its average volume of 415,390. Collegium Pharmaceutical, Inc. has a one year low of $20.83 and a one year high of $40.95. The company's 50 day simple moving average is $37.61 and its 200-day simple moving average is $32.17. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 32.08 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million for the quarter, compared to analysts' expectations of $147.66 million. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on COLL. Piper Sandler reaffirmed an "overweight" rating and set a $39.00 price target (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Truist Financial increased their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a "buy" rating in a report on Monday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $39.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.